LawFinance Limited Overview
LawFinance Limited is a distressed, now-unlisted Australian holding company whose sole remaining operating business was National Health Finance, an Arizona-based US medical lien funder that buys, or lends against, medical receivables arising from motor-vehicle personal-injury cases and is repaid from case settlements. Originally an Australian litigation and disbursement funder under the JustKapital brand, the group pivoted to the US through the September 2018 acquisition of NHF, financed with heavy acquisition debt. That leverage, extended collection cycles (around 30 months), COVID-era settlement delays and large impairments on contractual claims against medical providers produced six consecutive years of losses, a 2021 debt-for-equity restructure, a second creditor-led restructure in 2023–24, a net asset deficiency of US$35.3 million at December 2022, a two-year trading suspension and delisting in April 2025. Its residual value proposition rests on running off its receivables books and the unproven Trident Health Group hospital-receivables joint venture.
Company's own description (FY2022 Annual Report). During FY2022 the group operated a medical lien funding business in the United States. National Health Finance Holdco, LLC and its subsidiaries operate from Arizona with the ability to provide funding in 22 US states. Funding is provided by purchasing medical lien claims or by extending loan funding (lines of credit) to medical service providers secured against pools of medical lien claims. The underlying claims generally relate to medical treatment of not-at-fault individuals injured in motor vehicle accidents (Michigan, a no-fault state, being the exception). NHF purchases or lends against a lien, or obtains a letter of protection, over medical receivables from healthcare providers and hospitals; it is repaid when the at-fault party or its insurer pays on conclusion of the personal injury litigation, by settlement or judgment.
The company described a three-sided value proposition: injured plaintiffs gain access to medical care they would otherwise likely not receive; medical providers gain liquidity and shed administrative burden rather than waiting years for case resolution; and plaintiff lawyers benefit because there is no gap in care, which helps maximise the claim.
Revenue model. The business is a specialty-finance, balance-sheet lending model, not a product, subscription or licensing business. Under AASB 9, medical lien receivables are classified as purchased-or-originated credit-impaired (POCI) financial assets at amortised cost; revenue is recognised as effective interest, and changes in expected cash flows run through profit or loss as impairment gains or losses. Consequently "revenue" can be negative in years of heavy impairment (FY2022 total revenue was negative US$16.4 million). Minor other revenue lines historically included office rental income and insurance commissions (after-the-event insurance broking in the Australian era).
Value chain position. NHF sits between healthcare providers (the asset originators), plaintiff law firms (who control case progress and settlement), and liability insurers (the ultimate payers). It holds no clinical responsibility and is not obliged to purchase any specific lien.
Customer types and end-markets. Counterparties are US medical service providers (chiropractic, imaging, surgical, physician practices, and, via Trident HG, hospital emergency departments) and indirectly plaintiff law firms. The end-market is US motor vehicle personal-injury litigation, with exposure concentrated in Arizona, Texas and Michigan among the 22 eligible states.
Historical (discontinued) Australian businesses. Until 2021 the group also operated JustKapital Finance (disbursement funding for SME law firms — financing independent medical, psychological and radiology reports and other third-party costs; plus short-term funding of under 12 months to law firms), a litigation funding division (case funding for plaintiffs, largely spun into a trust in 2017), and after-the-event insurance broking. These ceased to be controlled by the group during FY2021.
Independent characterisation. LawFinance is best understood as a sub-scale, over-levered specialty credit vehicle in run-off. Its asset is a long-duration, binary-outcome receivables book whose value depends on third-party litigation and on the cooperation of medical providers. The capital structure (a senior asset-backed facility, a separate SPV facility, a corporate syndicated acquisition facility and capitalising convertible notes) was layered in a way that the 2021 independent expert (Grant Thornton) described as sub-optimal, and that ultimately left equity holders with negligible residual value.
Strategy
Stated strategy (FY2022 Annual Report and 28 Feb 2023 preliminary results). Management set out four strategic priorities:
Historical strategic themes. Under Daniel Kleijn (2021–2023), the stated ambition after the 2021 restructure was for NHF to become "America's leading medical financier," rebuilding provider relationships and adding the LOC product for larger provider groups (2022). The May 2022 raise was intended to fund "Phase 2" growth; a committed CCN funding offer from an Asian investment group was being negotiated in early 2023.
ESG commitments, cost programmes with targets, medium-term guidance. No ESG commitments disclosed. No medium-term financial targets or guidance have been issued since the suspension. The last 24 months (Oct 2024–Oct 2026) contain no announced initiatives beyond run-off and delisting.
Products & Services
National Health Finance (US, continuing until run-off)
| Product | Description | Target customer | Launch / status | Pricing model |
|---|---|---|---|---|
| Medical lien purchase | Outright purchase of a provider's lien or letter of protection over an invoice for treatment of a not-at-fault motor-vehicle injury victim | Chiropractors, imaging centres, physicians, surgical groups in 22 states | Since 1999; originations paused end-3Q 2022 | Purchase at c.30% of face value; target collection 1.4–1.6x investment |
| Provider lines of credit | Loan funding secured against pools of medical lien claims | Medical provider groups | Pre-2022 | Interest/fee-based (rates not disclosed) |
| Letter-of-credit (LOC) funding | New 2022 product targeting larger provider groups; drove most of the c.US$8m 1H2022 originations | Larger medical provider groups (e.g., two Texas providers) | Launched 1H2022 | 16% p.a. interest earned on US$5.3m repaid Sept–Oct 2022 |
| Funding of ancillary medico-legal services | NHF funded services such as 3D anatomical schematics from MRI data provided by Multus Medical LLC (a related party of former director David Wattel) for injury claims | Plaintiffs via providers/law firms | Disclosed FY2022 | — |
Trident Health Group (US joint venture, development stage)
| Item | Detail |
|---|---|
| Structure | JV formed in 2022 between LawFinance and two partners (partners not named publicly in sources retrieved) |
| Proposition | Purchase hospital emergency-department receivables where third-party liability insurance exists. US federal rules indicate Medicaid and Medicare should not pay where a third-party liability insurer can reasonably be expected to cover costs; Trident aims to help hospitals comply by buying these receivables instead of passing them to Medicaid/Medicare |
| Key contract | Supplier Service Agreement with the largest US hospital management company, fully executed March 2023 |
| First site | First hospital (Phoenix area, Arizona) targeted under a User Agreement from April 2023 as proof of concept |
| Status | As of the September 2024 quarter, no hospital funding agreements had been executed; target geography Southwestern US and Texas |
| Funding | No debt facility available for Trident originations as of March 2023 |
Discontinued Australian portfolio (pre-2021)
| Product | Description | Period |
|---|---|---|
| Disbursement funding (JustKapital Finance) | Pays law firms' third-party disbursements (expert, medico-legal reports) on behalf of clients; repaid on case resolution | 2016–2021 |
| Macquarie Medico Legal | Independent medical, psychological and radiology reports for negligence victims | Acquired Jan 2016 |
| Short-term funding | Loans to law firms under 12 months | 2016–2021 |
| Litigation (case) funding | Funding of meritorious plaintiff claims in exchange for share of proceeds; appeal, estate, portfolio and settlement finance | 2015–2017 (spun into trust), residual to 2021 |
| After-the-event insurance broking | Placement of adverse-costs insurance | to 2021 |
| Investigation and claim management services | Support services to claimants | to 2021 |
Financial Narrative
Data basis. The most recent five fiscal years for which audited figures were verified are FY2018–FY2022 (FY2022 Annual Report five-year summary and primary statements). FY2024 accounts are not publicly disclosed (company delisted before the reporting deadline). Blank cells = not disclosed in sources reviewed. All figures US$ thousands unless noted.
Income statement
Margins. Gross, operating, EBITDA and net margins are not meaningful because revenue was negative in FY2019, FY2020 and FY2022 and near zero in FY2021. Revenue CAGR is likewise not computable (sign change).
Commentary. The trend is one of persistent losses compounding into a deep equity deficiency. FY2020 was the inflection to crisis: a US$78.1m loss as COVID froze settlements and the NHF book was written down against acquisition-era carrying values. The May 2021 restructure cut finance costs (from US$11.5m in FY2021 to US$8.6m in FY2022) and the FY2021 loss narrowed to US$21.2m. However FY2022 relapsed to a US$31.1m loss due to c.US$23m of net impairments, primarily on lien claims that had converted into contractual and damages claims against US providers (mostly in the EFI book, and Michigan claims across both books). Operating expenses were cut sharply: administration and other expenses halved (US$4.1m to US$2.0m) and employee costs fell from US$4.2m to US$3.9m, with a further step down to a targeted US$200–250k monthly opex from early 2023.
Balance sheet
Commentary. The balance sheet shrank by 59% in FY2022 as receivables were impaired, while debt barely moved, taking the net deficiency from US$10.5m to US$35.3m. All lender facilities were classified as current because of covenant breaches. The equity-classified CCN (US$14.5m) flattered reported equity; economically the deficiency was larger.
Cash flow
Commentary. Because lien purchases and facility repayments are classified within operating activities, OCF understates the gross collection capacity of the book: collections rose 9% to US$16.5m in FY2022, but US$9.6m was reinvested in new liens, US$3.2m repaid working capital facilities and US$5.2m went to interest and fees. Equity raises were the only net source of liquidity. By the September 2024 quarter, PFG-book collections had fallen to US$0.5m per quarter, consistent with a contracting book in run-off.
Ratios
ROE, debt/equity and net debt/EBITDA are not meaningful (negative equity and negative EBITDA). ROIC, asset turnover and cash conversion cycle are not meaningful for a balance-sheet lender with negative revenue; the relevant operational analogue is the c.30-month average collection period.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Reported Segments by Period
| Period | Reported segments |
|---|---|
FY2017–FY2018 | JustKapital Finance (disbursement + short-term funding); Litigation Funding; National Health Finance (from Sep 2018) |
FY2019–FY2020 | Short-Term/Disbursement Funding (Australia); National Health Finance (US) |
FY2021–FY2023 | National Health Finance (US medical lien funding); all other operations and head office costs (Australia corporate). Australian businesses presented as discontinued in FY2021 |
Revenue by Segment
| Metric | FY2021 | FY2022 |
|---|---|---|
NHF net result from medical lien funding (USD K) | -3,079 | -17,017 |
NHF interest income on letter-of-credit product (USD K) | 0 | 444 |
Other revenue incl. corporate (USD K) | 1,392 | 143 |
Total group revenue, continuing (USD K) | -1,687 | -16,430 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Per-Share Data
| Metric | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Total revenue and other income (USD K, 5-yr summary basis) | 4,554 | -656 | -7,519 | 357 | -16,430 |
Total revenue, continuing ops (USD K, P&L basis) | — | — | — | -1,687 | -16,430 |
Gross profit / (loss) (USD K) | — | — | — | -1,744 | -16,438 |
EBIT excl. discontinued ops (USD K) | -8,619 | -9,910 | -35,054 | -10,495 | -22,435 |
Finance costs (USD K) | — | — | — | 11,474 | 8,642 |
Loss before tax, continuing (USD K) | — | — | — | -21,969 | -31,077 |
Loss after tax (USD K) | -11,548 | -23,256 | -78,136 | -21,229 | -31,077 |
Basic & diluted loss per share (US cents) | -4.60 | -4.70 | -867.89 | -73.31 | -55.56 |
Dividends per share (US cents) | 0 | 0 | 0 | 0 | 0 |
Share price at year end (AUD) | 0.07 | 0.06 | 0.03 | 0.76 | 0.06 |
Balance Sheet
| Metric | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
Total assets (USD K) | — | 48,171 | 19,887 |
Cash and cash equivalents (USD K) | — | 5,101 | 1,460 |
of which unrestricted cash (USD K) | — | 4,319 | 1,056 |
Medical lien receivables at amortised cost, current (USD K) | — | 12,372 | 8,794 |
Medical lien receivables at amortised cost, non-current (USD K) | — | 29,070 | 9,072 |
Borrowings, current (USD K) | — | 38,323 | 53,249 |
Borrowings, non-current (USD K) | — | 17,818 | 141 |
Total borrowings (USD K) | — | 56,141 | 53,390 |
Net debt excl. leases (USD K) | — | 51,040 | 51,930 |
Total liabilities (USD K) | — | 58,650 | 55,141 |
Total equity / (deficiency) (USD K) | -47,559 | -10,479 | -35,254 |
Goodwill and intangibles (USD K) | — | 0 | 0 |
Working capital (USD K) | — | -21,923 | -44,272 |
Debt Facilities
| Facility | Lender | Drawn / principal | Status |
|---|---|---|---|
Asset-backed facility (PFG Book) | Partners for Growth | US$10.8m drawn (FY2021: US$16.0m) | In amortisation since Nov 2022; undrawn limits cancelled; min. US$250k cash covenant |
SPV facility (EFI Book) | Efficient Frontier Investing (EFI) syndicate | Not separately extracted | Covenant testing holiday to 31 Mar 2023; LVR breach expected; limited group guarantee |
Syndicated Acquisition Facility (SAF) | SAF lender syndicate | US$18.3m (A$26.9m) | Asset Coverage covenant breached at 31 Dec 2022; breach formally reported 27 Mar 2023 |
Capitalising Converting Notes (CCN) | Noteholders | A$20.5m principal; equity-classified US$14.5m | Maturity extended to 31 Mar 2023; proposed further extension to 30 Jun 2025 at 8% |
Cash Flow
| Metric | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Cash collections from customers (USD K) | — | — | — | 15,156 | 16,521 |
Payments for medical liens (USD K) | — | — | — | -3,577 | -9,583 |
Net operating cash flow (USD K) | — | — | — | -12,066 | -7,375 |
Capex — PP&E (USD K) | — | — | — | -154 | -5 |
Free cash flow, OCF less capex (USD K) | — | — | — | -12,220 | -7,380 |
Proceeds from share issues (USD K) | — | — | — | 13,321 | 4,502 |
Dividends paid (USD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (USD K) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 |
|---|---|---|
ROA on year-end assets (%) | -44.1 | -156.3 |
Current ratio (x) | 0.46 | 0.19 |
Interest coverage, EBIT / finance costs (x) | -0.91 | -2.60 |
Revenue by Region and Operating Metrics (count)
| Metric | FY2021 | FY2022 |
|---|---|---|
Total group revenue, continuing (USD K) | -1,687 | -16,430 |
Number of US states in which NHF can fund (count) | 22 | 22 |
Share Price
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
Share price, June closing (AUD) | 0.068 | 0.041 | 1.19 | 0.165 | 0.005 | 0.005 | 0.005 |
Share Price & Returns
| Date | Raising | Price | Amount |
|---|---|---|---|
Nov 2017 | Private placement | — | A$4.4m |
Nov 2018 | Rights issue | A$0.08 | — |
Jan–Feb 2020 | Placement and rights issue | A$0.064 | — |
May 2021 | Restructure placement and equity raise | Various | US$13.3m cash proceeds (FY2021) |
May 2022 | Entitlement offer and placement with attaching options (A$0.55 exercise, expiry 30 Apr 2024) | A$0.275 | A$6.4m gross |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance. None. The last forward-looking statements (March 2023) concerned survival funding, the restructure and the Trident HG launch. Since the September 2024 quarter the business has been in a low-cost run-off posture, and since 29 April 2025 the company has made no public disclosures.
Consensus expectations. None (no coverage).
Bull case
-
A clean, debt-light shell: the 2023–24 restructure converted the SAF debt and removed the EFI SPV, potentially leaving a vehicle with large tax losses (accumulated losses US$180m) and an experienced owner group.
-
Recovery optionality: impaired contractual claims (including c.US$7.3m original cost Michigan claims) could produce recoveries above written-down values, which the company itself described as having a very broad range.
-
Trident HG: if hospital funding agreements are ever executed under the March 2023 Supplier Service Agreement, the model addresses a large hospital receivables pool with a regulatory tailwind.
Bear case
-
Run-off dynamics: collections fell to US$0.5m per quarter by late 2024, with no new originations since late 2022 and no funding facility.
-
Equity is likely deeply subordinated: at December 2022 liabilities exceeded assets by US$35.3m, and creditors and funders now control a majority of the register.
-
No market or disclosure: delisted, no published accounts beyond FY2023, minimal governance transparency and no liquidity for minority holders.
Key catalysts and monitorables (next 12 months)
-
Any ASIC lodgements (financial reports, change of officeholders, external administration or deregistration notices).
-
Outcomes of contractual claim litigation in Michigan and against other providers.
-
Any Trident HG hospital agreement or sale of the JV interest.
-
Any take-private, scheme, capital return or wind-up proposal from major holders (Lucerne, the MIS, EFI, PFG).
-
Release (or non-release) of FY2024 and FY2025 accounts to members.
Analyst verdict. LawFinance Limited is a case study in how leverage, asset duration mismatch and acquisition overpayment can destroy a small listed specialty lender. The September 2018 purchase of National Health Finance transformed an Australian disbursement funder into a US medical lien financier, but it was financed with layered acquisition, asset-backed and convertible debt against receivables that take around 30 months to collect and depend on third-party litigation. When COVID stalled settlements in 2020, the model broke: the group lost US$78m that year, needed a debt-for-equity restructure in 2021, and, after a brief origination recovery in 1H2022, recorded c.US$23m of further impairments as lien exposures turned into contested claims against medical providers. By December 2022 the group had a US$35.3m net deficiency, a 0.19x current ratio, breaches across all lender groups and directors openly contemplating voluntary administration.
What followed was a creditor- and anchor-shareholder-led restructuring, a two-year suspension and removal from the ASX on 29 April 2025. Ownership now sits mainly with Lucerne-associated entities, a managed investment scheme and former lenders. For an outside investor, there is no investable security in practical terms: no quotation, no recent accounts, no guidance and no coverage. Any residual value lies in recoveries from impaired claims, potential tax losses and the long-dated, so far unrealised Trident HG option, all of which accrue first to the controlling holders.
Our assessment is that LawFinance should be treated as a non-operating, run-off entity with negligible minority equity value. The only scenarios that would change that view are a recovery windfall on contractual claims or a funded Trident launch, neither of which has been evidenced publicly since late 2024. Stakeholders should monitor ASIC filings for external administration, deregistration or any member distribution proposal.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure | Background | Notes |
|---|---|---|---|---|
Michael Henshaw | Director (associated with Lucerne LCF Pty Ltd holding) | Director interest notice 17 Jun 2024 | Not publicly detailed in sources reviewed | Indirect interest 63,127,985 shares (19.99%) |
Christopher Beng | Director (associated with Law Finance Managed Investment Scheme holding) | Director interest notice 17 Jun 2024 | Not publicly detailed | Indirect interest 52,098,331 shares (16.50%) |
Anthony Murphy | Non-Executive Director | Since 31 Oct 2017 | CEO, Lucerne Investment Partners; founded Canaccord Genuity's Australian wealth business; BEc and BCom (ANU) | Chaired Remuneration & Nominations Committee; 210,409 shares and 100,000 options per April 2024 notice |
Tim Storey | — | Agreement from 1 Apr 2015 | Barrister and solicitor; former partner at a leading NZ law firm; Chair of Stride Property Group (NZX: SPG), Director of Investore Property (NZX: IPL); co-founder of JustKapital | Chaired Audit & Risk Committee (FY2022); options expired 30 Apr 2024 |
Daniel Kleijn | Non-Executive Director from 28 Feb 2023 (former CEO/MD) | CEO c.Dec 2020–Feb 2023 | Former Managing Director at Lazard and UBS; Master of Economics, University of Groningen | — |
Board of Directors — David Wattel
| Name | Role | Exit |
|---|---|---|
David Wattel | NED; NHF co-founder; founder of Wattel & York personal injury firm; JD Arizona State | Resigned 28 Feb 2023 |
Jane Lamming | Independent NED, Audit & Risk chair; GC and CCO of Ausbil Investment Management | 1 Sep 2021 – 1 Mar 2022 |
Diane Jones | Former CEO/CFO of JustKapital/LawFinance | — |
Philip Kapp | Founder and Executive Chairman | Resigned Oct 2017 |
Executive Leadership Team
| Name | Title | Since | Background | FY2022 total remuneration (USD) |
|---|---|---|---|---|
Phil Smith | CEO (from 28 Feb 2023), CFO and Company Secretary (secretary from 14 Oct 2022) | 8 Dec 2020 | 20+ years restructuring/turnaround advisory, 13 years at Deloitte and KPMG (Australia, Hong Kong, Vietnam); BEc, Master of Professional Accounting | 371,329 |
Richard Cruz | President and General Counsel – NHF; CEO – NHF (from 28 Feb 2023) | 25 Apr 2016 | General counsel of NHF | 411,339 |
Daniel Kleijn | CEO and MD (to 28 Feb 2023) | c.Dec 2020 | See board | 724,495 |
Marialena Ziska | Chief Revenue Officer – NHF | 3 Jun 2019 – 10 Jun 2022 | — | 101,411 |
Directors' Remuneration
| Name | Salary & fees | Cash bonus | Super | Termination | Options (share-based) | Total |
|---|---|---|---|---|---|---|
Daniel Kleijn | 380,880 | 190,440 | 17,313 | 0 | 135,862 | 724,495 |
Tim Storey | 55,401 | 0 | 0 | 0 | 634 | 56,035 |
Anthony Murphy | 31,406 | 0 | 3,219 | 0 | 634 | 35,259 |
David Wattel | 0 | 0 | 0 | 0 | 1,268 | 1,268 |
Jane Lamming | 5,331 | 0 | 533 | 0 | 0 | 5,864 |
Phil Smith | 188,305 | 103,876 | 19,447 | 0 | 59,701 | 371,329 |
Richard Cruz | 241,638 | 110,000 | 0 | 0 | 59,701 | 411,339 |
Marialena Ziska | 73,933 | 36,700 | 0 | 11,673 | -20,895 | 101,411 |
Total | 976,894 | 441,016 | 40,512 | 11,673 | 236,905 | 1,707,000 |
Major Shareholders
| Holder | Shares | % |
|---|---|---|
J P Morgan Nominees Australia | 71,873,855 | 22.76 |
Lucerne LCF Pty Limited | 63,127,985 | 19.99 |
Law Finance Managed Investment Scheme | 52,098,331 | 16.50 |
EFI Cayman SPC (NHF SPV III Seg Port A/C) | 28,787,111 | 9.12 |
Lucerne Finance Pty Limited | 8,562,754 | 2.71 |
Portfolio Services Pty Limited | 7,743,835 | 2.45 |
Australian Philanthropic Services Foundation (APS Foundation A/C) | 5,389,722 | 1.71 |
Partners for Growth VI LP | 5,150,618 | 1.63 |
Partners for Growth V LP | 5,150,617 | 1.63 |
Aquasia Pty Ltd (Aquasia Private Invest A/C) | 4,577,460 | 1.45 |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Type | Relative positioning vs LawFinance/NHF |
|---|---|---|---|
US medical lien / medical receivables funding | Numerous private regional lien funders and provider-financing firms (fragmented market; no dominant public player) | Private | NHF was described as sub-1% share of a US$11bn+ market (2017, per NHF founder) |
US pre-settlement / plaintiff finance | Oasis Financial | Private | Larger, consumer-facing pre-settlement funding; different asset (plaintiff advances) |
US pre-settlement / plaintiff finance | US Claims | Private | Adjacent plaintiff funding |
US pre-settlement / plaintiff finance | Legal-Bay | Private | Adjacent plaintiff funding |
Global commercial litigation finance | Burford Capital (NYSE/LSE: BUR) | Listed | Vastly larger, commercial-claims focus; not a direct medical lien competitor |
Global litigation finance (ex-Australia origin) | Omni Bridgeway (ASX: OBL) | Listed | Large ASX-listed funder; competed with JustKapital's former Australian litigation funding |
Litigation finance (Australian origin) | Litigation Capital Management (AIM: LIT) | Listed | Former Australian peer to JustKapital litigation arm |
Australian class-action funding | CASL, ICP, Woodsford (Australia ops) | Private | Competitors to the discontinued Australian case funding |
Australian disbursement funding | Private disbursement funders and specialist law-firm lenders | Private | Competitors to the discontinued JustKapital Finance |
Hospital third-party-liability recovery (Trident analogue) | Revenue-cycle and TPL recovery vendors serving US hospitals | Private / divisions of large RCM groups | Trident would have faced incumbent service providers rather than funders |
Peer Comparison FY2022
| Dimension | LawFinance (FY2022) | Large listed litigation funders (Burford, Omni Bridgeway, LCM) |
|---|---|---|
Scale | US$19.9m total assets, shrinking | Hundreds of millions to billions in assets |
Funding model | Asset-backed debt at 85% advance; breached covenants | Diversified balance sheet plus third-party fund management |
Asset type | Small-ticket, high-volume medical liens | Large commercial claims and portfolios |
Profitability | Six consecutive annual losses | Variable but capable of profits from realisations |
R&D intensity | — | None (not applicable) |
Recent Developments
The 18 months to October 2026 (April 2025 onward) contain essentially one public event — the delisting — after which the company ceased ASX disclosure.



